Related Experiment Video
Updated: Jan 12, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Active and resolved HCV infections among people with new HIV-1 diagnoses in Germany, 2009-2019
Daniel Ivanusic1, Amare Eshetu1, Hussein Al-Shehabi1
1Unit 18 HIV and Other Retroviruses/Sexually Transmitted Bacterial Pathogens (STI) and HIV, Department of Infectious Diseases, Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany.
Insights
The introduction of direct-acting antivirals (DAAs) has increased the rate of resolved Hepatitis C Virus (HCV) infections in individuals newly diagnosed with Human Immunodeficiency Virus (HIV) in Germany. However, unmet needs persist, particularly for people who inject drugs and individuals of non-German origin.
Area of Science:
- Infectious Diseases
- Hepatology
- Public Health
Background:
- HIV and HCV share transmission routes, with co-infection accelerating liver disease progression.
- Analysis of new HIV-1 diagnoses in Germany examines active or resolved HCV infection.
- The study period coincides with the introduction of direct-acting antivirals (DAAs) for HCV treatment.
Purpose of the Study:
- To assess the trends in active and resolved Hepatitis C Virus (HCV) infections among individuals newly diagnosed with Human Immunodeficiency Virus (HIV) in Germany.
- To evaluate the impact of direct-acting antivirals (DAAs) on HCV treatment outcomes in this population.
- To identify disparities in HCV infection and resolution rates among different demographic and transmission groups.
Main Methods:
- Retrospective analysis of residual blood samples from 16,539 individuals with new HIV-1 diagnoses between 2009 and 2019.
- Screening for HCV antigen and/or antibodies, followed by RT-qPCR for active or resolved infection.
- Statistical analysis correlating HCV status with socio-demographic data and transmission routes.
Main Results:
- Overall HCV seroprevalence was 6.2%, with a stable trend.
- The proportion of resolved HCV infections significantly increased post-DAA introduction (from 33.0% to 48.2% by 2019).
- People who inject drugs (PWIDs) showed the highest prevalence (73.7%) but the lowest resolution rate (29.4%).
- Individuals of non-German origin had higher active/resolved case proportions (8.8% vs. 4.3%) and lower resolution rates (27.8% vs. 34.0%) compared to German-born individuals.
Conclusions:
- The proportion of resolved HCV infections has risen following DAA implementation in Germany.
- Significant unmet diagnostic and therapeutic needs for HCV exist among PWIDs.
- Higher active/resolved HCV case proportions and lower resolution rates in individuals of non-German origin warrant targeted public health interventions.
Background:
HIV and HCV share similar routes of infection. Individuals carrying both viruses experience a faster progression of the liver disease. We have analyzed people with new HIV-1 diagnoses in Germany for active or resolved HCV infection for over ten years. The time period covers the introduction of direct acting antivirals (DAA), a paradigmatic shift in HCV therapy.
Methods:
A central component of the HIV surveillance in Germany is the notification of new diagnoses. Residual blood samples from 16,539 people with new HIV-1 diagnoses reported between 2009 and 2019 were examined for HCV antigen and/or antibodies. Reactive cases were further investigated for active or resolved HCV infection by RT-qPCR. The results were analyzed with socio-demographic information from the notification forms.
Results:
The study includes samples from 48.0% of all notified HIV-1 diagnoses. The seroprevalence of cases with HCV antigen, antibodies or both, representing active and resolved infections was 6.2% with stable seroprevalence. The average proportion of resolved infections among those was 33.0% with a significant increase since the introduction of DAAs in 2012 (pTrend_2012-2019 = 0.028) reaching 48.2% in 2019. The highest proportion of active and resolved cases (73.7%) was found in people who inject drugs (PWIDs). This transmission group had the lowest percentage of resolved infections with 29.4%. The proportion of active and resolved cases in persons with heterosexual mode of transmission (HET) and in men who have sex with men (MSM) was 3.8% and 2.6%, respectively. The peak percentage of resolved infections was found in MSM (40.0%), followed by HET (36.6%). The proportion of active and resolved cases among individuals with non-German origin was higher than in people with German origin (8.8%, versus 4.3%; p < 0.001) and the proportion of resolved HCV infections lower (27.8% versus 34.0%; p = 0.027).
Conclusions:
The proportion of resolved HCV infections among people newly diagnosed with HIV-1 increased after the introduction of DAAs in Germany. The high prevalence and the low proportion of resolved HCV infections reveal that unmet diagnostic and therapeutic needs exist among PWIDs. The higher proportion of active and resolved cases among individuals of non-German origin particularly requires greater public health attention.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections

